2022 SITC MxIF-SIG Initiative
Pathology and specific multiplex imaging, which allows for simultaneous characterization of multiple markers, has been more readily investigated and is envisioned to be critical for the selection of novel therapeutics in the future. Clinical adoption of these technologies, however, remains limited due to various challenges including standardized data reporting methods.
To address this barrier in the field, the SITC Pathology Committee has developed the Multiplex Immunofluorescence – Special Interest Group (MxIF-SIG) Initiative. The primary goal of this initiative is to develop a consensus checklist for multiplex IF and immune histochemistry (IHC) data validation and reporting.
Click here to learn more about this initiative and to view the enduring materials